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Background: The gastrointestinal (GI) tract is one of the most common extranasal sites in extranodal NK/T-cell
lymphoma (ENKTL). However, data regarding ENKTL involving the GI tract are relatively scarce. Thus, we performed
a multicenter, multinational retrospective study to analyze clinical features and treatment outcomes of ENKTL
involving the GI tract.
Patients and methods: Patients with ENKTL involving the GI tract diagnosed in twelve participating centers
between 1991 and 2012 were retrospectively analyzed from five Asian countries.
Results: The analysis of 81 patients with ENKTL involving the GI tract revealed that more than 60% of patients
presented as advanced disease with B symptoms. 55 patients (68%) had GI manifestations including abdominal pain
(n = 26, 32%), GI tract bleeding (n = 17, 21%) and bowel perforation (n = 12, 15%). The most common GI site was the
small intestine, including the jejunum and ileum (n = 57, 70.3%). There were 34 patients (42%) who received systemic
chemotherapy while 33 patients (41%) underwent surgery plus chemotherapy. However, 35 patients (43%) died due to
disease progression, and treatment-related mortality including sepsis occurred in 17 patients (21%). Thus, the median
overall survival was 7.8 months (95% Confidence interval: 3.9 – 11.7 months). Patients who could undergo surgery plus
chemotherapy showed a trend of better survival than those treated with chemotherapy alone.
Conclusion: Overall, the data indicated that ENKTL involving the GI tract has a dismal prognosis despite active
treatment including chemotherapy and surgery. Thus, more effective treatment strategies are required for this
disease entity.
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Extranodal NK/T cell lymphoma (ENKTL) is known to
cause localized disease involving midline facial structures
such as the nasal cavity and nasopharynx [1]. However,
the occurrence of ENKTL outside the nasal areas such
as the skin, liver, soft tissue and gastrointestinal (GI) tract
is also common. Furthermore, cases involving extranasal
areas frequently present as more advanced disease and
have poorer prognoses than nasal cases. Accordingly, a
recent retrospective study showed that the worst treatment
outcomes were associated with skin and soft tissue
involvement, especially in cases of advanced disease [2].
However, data regarding ENKTL involving the GI tract
are relatively scarce [3], although the GI tract is the most
common site of extranodal organ involvement in patients
with non-Hodgkin lymphoma (NHL) [4,5]. A previous
retrospective analysis of 581 patients with intestinal NHL
reported a frequency of 3.1% of ENKTL (n = 18) and
poorer prognosis than B-cell lymphomas [6]. In the study,
however, because of the small number of ENKTL patients,
the results might not be representative. Furthermore, the
treatment outcomes of various treatment modalities for
patients with GI tract ENKTL have hitherto not been
compared. The role of surgery in GI tract ENKTL is
also undefined, although it appears to be an important
modality in the management of localized intestinal B-cell
lymphomas [7]. As a result, there is still no established
treatment strategy for ENKTL involving the GI tract.
In this study, we conducted a multicenter retrospective
analysis of a cohort of Asian patients with GI tract ENKTL,
in order to define the clinicopathologic features, and




Patients with a diagnosis of ENKTL involving the GI
tract diagnosed in twelve participating centers were
retrospectively analyzed. Patients were accrued during
two periods, from 1991 – 2000, the pathologic diagnosis
was based on the Revised European-American Lymphoma
(REAL) classification. From 2001 – 2012, the diagnosis
was based on World Health Organization (WHO) clas-
sification criteria. Pathologic data of patients diagnosed
according to the REAL classification were reviewed to
ensure that they fully fulfilled the WHO criteria. The
GI tract was considered as primarily involved if patients
presented initially with GI symptoms or complications.
Patients who presented with nasal lesions were also
analyzed if the involvement of GI tract was found at
the staging work-up. Tumor locations were determined
using imaging findings, such as computerized tomography
(CT), or surgical findings if surgical resection was
performed. The Ann Arbor staging system was used forstaging investigations included complete blood counts,
serum biochemistry, serum lactate dehydrogenase (LDH),
bone marrow aspiration and trephine biopsy, nasal
endoscopic examination and computed tomographic (CT)
scanning of the involved organ(s), chest and abdomen.
Clinical data analysis
Clinicopathologic data including demographics, primary
presentation such as GI manifestations, stage, Eastern
Cooperative Oncology Group (ECOG) performance status,
serum LDH, the presence of B symptoms, and tumor
location were analyzed. Treatment modalities, including
surgery and chemotherapy (first-line regimens) were also
analyzed. Potential risk factors were analyzed including
the International Prognostic Index (IPI) as well as the NK
prognostic index (NKPI, as determined by presence of B
symptoms, stage III/IV, elevated serum LDH, involvement
of regional lymph nodes) [8]. This study was approved
by the Institute Review Board of Samsung Medical Center
(No. 2013-07-079).
Statistical analysis
Overall survival (OS) was calculated from the date of
diagnosis to the date of the last follow-up visit or death
from any cause. Survival was estimated using Kaplan–
Meier curves and compared by the log-rank test. The
follow-up duration was calculated by the method of
Kaplan-Meier estimate of potential follow-up as previously
reported [9].The Cox proportional hazard regression
model was used in multivariate analyses to identify
prognostic factors. Two-sided P-values < 0.05 were
considered significant.Results
Patient characteristics
Eighty-one patients were included in this retrospective
analysis. The median age of patients at diagnosis (45 years,
range: 17–79 years), and male predominance (69%, 56/81)
were similar to the overall characteristics reported for
ENKTL [10]. However, approximately 65% of patients had
two or more sites of extranodal involvement (Table 1).
Thus, the proportion of advanced disease was over 60%,
and B symptoms were also frequently observed (63%,
51/81). As a result, risk stratification based on the NKPI
showed that > 50% of patients belonged to the high-risk
category of group 4. In contrast, the IPI showed only 11
patients were grouped as high-risk, because the majority
of patients were younger than 60 years of age (Table 1). GI
manifestations were the main symptom at diagnosis in 55
patients (68%) and included abdominal pain (n = 26, 32%),
GI tract bleeding (n = 17, 21%) and bowel perforation
(n = 12, 15%). Thus, a substantial number of patients
underwent surgery to remove their primary mass for
Table 1 Patient characteristics
Characteristics Number (%)
Sex Male 56 (69)
Female 25 (31)
Age (years) ≤ 60 67 (83)
> 60 14 (17)
Performance status ECOG 0/1 54 (67)
ECOG ≥ 2 25 (31)
Missing 2 (2)
Extranodal involvement < 2 29 (36)
≥ 2 52 (64)
Serum LDH Normal 38 (47)
Increased 40 (49)
Missing 3 (4)
Ann Arbor stage I/II 18 (22)/11 (13)
III/IV 7 (9)/45 (56)
B symptoms Absence 30 (37)
Presence 51 (63)
Bone marrow invasion Absent 68 (84)
Present 7 (9)
Not evaluated 6 (7)
NK Prognostic Index Group 1/2 3 (4)/12 (15)
Group 3/4 21 (26)/42 (52)
Missing 3 (4)
International Prognostic Index Low/Low-intermediate 22 (27)/19 (24)
High-intermediate/High 26 (32)/11 (13)
Missing 3 (4)
Clinical presentation GI manifestation 55 (68)
Non-GI manifestation 26 (32)
Nasal involvement Absence 63 (78)
Presence 18 (22)
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26 patients (32%) presented as non-GI manifestations
including nasal obstruction (n = 6) or systemic symptoms
(n = 20) such as fever and night sweat. During the
evaluation of these 26 patients including endoscopic
examination of nasal cavity and CT scans of neck, chest
and abdomen-pelvis, the simultaneous involvement of
nasal cavity or nasopharynx as well as GI tract was
found in 18 patients (22%). Thus, these 18 patients were
pathologically diagnosed with ENKTL by biopsy of nasal
areas, and the involvement of GI tract was documented in
abdominal CT scan and/or positron emission tomography
(PET)/CT scan. The remaining eight patients out of 26
patients presented with non-GI manifestation also under-
went surgery to remove mass of GI tract for pathologic
diagnosis (Figure 1A).Pattern of GI tract involvement
ENKTL dominantly involved the small and large intestine
(n = 58, 72%) rather than stomach. The small intestine
was the most commonly involved site as 34 patients (42%)
had small intestinal disease only while 23 patients (28%)
had disease involving both the small and large intestine.
One patient had disease in the stomach, duodenum, and
jejunum, and the other patient presented with disease in
the stomach, duodenum and descending colon (Figure 1B).
Given a patient could involve multiple involvement of
GI tract such as small and large intestine, the absolute
number of involved parts of GI tract in this study was
higher than the number of patients. Hence, when we
analyzed the percentage of involvement through whole GI
tract, the most commonly involved part was ileum (29%).
Jejunum and cecum were 17% and 14%, respectively.
Thus, these three parts of GI tract accounted for
approximately 60% of GI site involvement (Figure 1C). In
addition, 17 patients (21%) had intra-abdominal involve-
ment in sites including the liver, pancreas, adrenal glands,
and peritoneum.Treatment
Out of the 55 patients presenting with GI manifesta-
tions, 37 patients first underwent resection of their pri-
mary mass lesion mainly for complications such as
bleeding or perforation (Figure 2). All but one patients
with bowel perforation underwent surgery. One patient
presenting as abdominal pain and the other patient pre-
testing as perforation received only supportive care be-
cause they could not undergo surgery owing to their
poor health status s (Figure 2). After surgery, 26 patients
received systemic chemotherapy, whereas 11 patients
did not. Sixteen patients who had widespread disease in-
cluding GI tract and other sites received systemic
chemotherapy (Figure 2). Among the 26 patients pre-
senting without GI manifestations, 18 received systemic
chemotherapy while 8 underwent surgery first. There-
fore, the initial treatment for these patients included
chemotherapy alone (n = 34, 42%), surgery plus chemo-
therapy (n = 33, 41%), and surgery alone (n = 12, 15%).
CHOP (cyclophosphamide 750 mg/m2 on day1, doxo-
rubicin 50 mg/m2 on day 1, vincristine 1.4 mg/m2 on
day 1, and prednisone 100 mg on days 1–5) or CHOP-
like chemotherapy regimens were used in 37 patients
whereas non-anthracycline-based or intensified chemo-
therapy such as SMILE (Methotrexate 2 g/m2 on day 1,
ifosfamide 1500 mg/m2 on days 2–4, etoposide 100 mg/
m2 on days 2–4, dexamethasone 40 mg on days 2 – 4, and
Escherichia coli L-asparaginase 6,000 U/m2 on days 8, 10,
12, 14, 16, 18, 20, n = 17), EPOCH (etoposide 50 mg/m2
on days 1–4, doxorubicin 10 mg/m2 on days 1–4, vincris-
tine 0.4 mg/m2 on days 1–4, cyclophosphamide 750 mg/m2
Figure 1 Clinical manifestation and gastrointestinal tract involvement. (A) Comparison of clinical manifestation and anatomic involvement
(B) Pattern of gastrointestinal tract involvement. (C) Frequency of involvement of each part of the GI tract by extranodal NK/T-cell lymphoma
from the esophagus to the recto-sigmoid colon (The percentage of each part of GI tract = the number of patients involving each part/total
number of involved parts in 81 patients × 100).
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VIPD (etoposide 100 mg/m2 on days 1–3, ifosfamide
1500 mg/m2 on days 1–3, cisplatin 33 mg/m2 on days
1–3, and dexamethasone 40 mg on days 1 – 4, n = 2),
ESHAP (etoposide 40 mg/m2 on days 1–4, methylpred-
nisolone 500 mg on days 1–4, cisplatin 25 mg/m2 onGI manifestations 
Abdominal pain (n = 26) 
Bleeding (n = 17) 






(n = 6) 
Other systemic 





Figure 2 Summary of treatment approaches.days 1–4, and cytarabine 2 g/m2 on day 5, n = 1),
gemcitabine-containing chemotherapy (n = 2), and
others (n = 3) were used in 30 patients. However, among
the 34 patients treated with systemic chemotherapy, 9
patients underwent surgery due to GI complications
during chemotherapy (Figure 2) including bowelurgery (n = 11) 
hemotherapy (n = 16) 
Surgery (n = 9)   
urgery + chemotherapy (n = 26) 
 (n = 1) 
therapy (n = 18) 
 + chemotherapy (n = 7) 
(n = 4)   
(n = 5)   
upportive care (n = 2) 
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tion (n = 3). Autologous (n = 3) or allogeneic
hematopoietic stem cell transplantation (HSCT, n = 5)
was done in eight patients as a consolidation treatment
after chemotherapy.
Treatment outcomes
With the median potential follow-up of 54.0 months (95%
Confidence interval (CI): 31.6 – 76.4 months), the median
OS was only 7.8 months (95% CI: 3.9 – 11.7 months). A
total of 54 patients died, including two patients who
did not receive any curative treatment. Among the 79
patients who received surgery or chemotherapy or
both, 35 patients died due to disease progression while
non-disease-related deaths were found in 17 patients
(Figure 3A). Sepsis accounted for 70% of non-disease-
related death (12/17), with seven patients dying from
sepsis after chemotherapy. In patients treated with surgery
plus chemotherapy, two patients died due to graft-
versus host disease (GVHD) after allogeneic HSCT,
and the remaining two other deaths included surgical
complication-related death and suicide (Figure 3A).
The comparison of outcomes according to chemotherapy
regimens showed no significant difference in the cause
of deaths among patients who received CHOP or
SMILE regardless of surgery although the proportion of
disease-related death was lower in patients who received
SMILE (35%, 6/17) than CHOP (57%, 21/37, Figure 3B).
The median OS of patients treated with surgery plus
chemotherapy was 21.3 months (95% CI: 8.2 – 34.4 months)
whereas the median OS of chemotherapy or surgery alone
was 7.2 (95% CI: 3.0 – 11.4 months) and 1.7 months (95%
CI: 0.36 – 3.0 months), respectively. Thus, surgery followed
by chemotherapy showed a tendency toward betterFigure 3 Comparison of treatment outcomes based on treatment mo
patients treated with chemotherapy or surgery or both. (B) There is no sig
chemotherapy regimens.outcomes compared with chemotherapy (Figure 4A).
However, these results might be related to the fact that pa-
tients who received chemotherapy had more advanced
disease and unfavorable characteristics compared with
patients who underwent surgery plus chemotherapy
(Table 2). When we compared the OS according to
chemotherapy regimens, patients who received non-
anthracycline-based or intensified regimens did not show
a significant survival difference compared with patients
who received CHOP or CHOP-like regimens regardless of
surgery (Figure 4B, C). The comparison of CHOP with
SMILE also showed no survival difference (data not
shown).Prognostic factors
The OS was not significantly different on univariate ana-
lysis according to age > 60 years, serum LDH elevation,
stage III/IV, B symptoms, location of GI tract involvement,
nasal involvement, or bone marrow invasion (P > 0.05).
Only extranodal involvement and performance status
were significantly associated with worse OS (P < 0.05).
Thus, patients who had involvement at two or more
than two extranodal sites and poor performance status
showed inferior OS. However, multivariate analyses failed
to show an independent prognostic factor for ENKTL
involving the GI tract. The prognostic model, IPI and
NKPI showed a significant association with poor OS
(Figure 5A, B).Discussion
This is a multinational, multicenter study analyzing to
date the largest number of patients with ENKTL involving
the GI tract. Although there may have been selectiondality and chemotherapy regimen. (A) Treatment outcomes for
nificant difference of death causes according to the type of
Figure 4 Analysis of survival outcomes based on treatments. (A) The comparison of overall survival shows better survival of patients treated
with surgery plus chemotherapy with marginal significance compared to chemotherapy alone. (B) The comparison of overall survival according
to the type of chemotherapy regimen, CHOP versus non-anthracycline based chemotherapy (non-CHOP) shows no difference in the surgery plus
chemotherapy group. (C) In the chemotherapy group, there is no difference between CHOP and non-CHOP regimens.
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results reflect the clinical features and treatment outcomes
of GI ENKTL. In this study, the majority of patients
presented with advanced disease and the simultaneous
involvement of other extranodal sites such as nasal tract.
Furthermore, multiple areas of involvement throughout
the GI tract were also frequent. Therefore, detailed deter-
mination of the extent of disease is necessary in patients
with ENKTL who present with GI tract disease. Our study
showed a predominant involvement of the small intestine,
especially the ileum and jejunum. This pattern of in-
volvement was different from B-cell lymphomas, which
more commonly involve the stomach, terminal ileum
and cecum. This frequent involvement of the jejunum
and ileum by ENKTL is similar to that of peripheral T-cell
lymphoma [6]. As ENKTL patients showed frequent
involvement of the jejunum and ileum as well as GI
complications such as bleeding and perforation, surgical
resection of the primary mass was inevitable for diagnosis
and treatment in the majority of our cases. After surgery,
systemic chemotherapy was originally planned in all
patients due to the nature of the systemic disease.
However 12 patients only underwent surgery withoutany adjuvant treatment in this study. The predominant
reason for not administering subsequent chemotherapy
was due to general poor-health post-operatively. As a
result, patients who underwent surgery alone showed
the extremely short survival duration (median OS:
1.7 months). On the other hand, the OS of patients
who underwent surgery followed by chemotherapy was
better than patients who were initially treated with
chemotherapy, although the statistical significance was
marginal (Figure 4A). Given the fact that stage I/II disease
and good performance status were more common in
patients who received surgery and adjuvant chemotherapy
(Table 2), the better outcome of surgery plus chemother-
apy than that of chemotherapy alone might be associated
with tumor burden and performance status. Nevertheless,
our study results suggested surgery plus chemotherapy
might be beneficial for patients who were eligible for
surgery such as localized disease and good performance
status.
The outcome of patients who received chemotherapy
only was extremely poor, with the majority of patients
dying due to disease progression (20/34, 59%, Figure 3A),
as compared with 12 patients dying from disease progres-
Figure 5 Analysis of survival outcomes based on prognostic models. (A) Patients belonged to groups 1 and 2 of the NKPI showed better
overall survival than groups 3 and 4 of the NKPI (B) High or high-intermediate risk group of the IPI showed worse overall survival than patients
with low or low-intermediate risk of the IPI.
Table 2 Comparison of characteristics based on treatment
Characteristics Surgery + Chemotherapy Chemotherapy P
Age (years)
≤ 60 25 (76) 30 (88) 0.13
> 60 8 (24) 4 (12)
Performance status
ECOG 0/1 27 (84) 20 (59) 0.03
ECOG ≥ 2 5 (16) 14 (41)
Extranodal involvement
< 2 15 (45) 7 (21) 0.04
≤ 2 18 (55) 27 (79)
Serum LDH
Normal 17 (52) 15 (44) 0.62
Increased 15 (45) 19 (56)
Missing 1 (3)
Ann Arbor stage
I/II 15 (45) 5 (15) < 0.01
III/IV 18 (55) 29 (85)
B symptoms
Absence 15 (45) 9 (27) 0.13
Presence 18 (55) 25 (73)
Bone marrow invasion
Absence 29 (88) 29 (85) 0.20
Presence 2 (6) 5 (15)
Not evaluated 2 (6) 0 (0)
Nasal involvement
Absence 30 (91) 19 (56) < 0.01
Presence 3 (9) 15 (44)
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Figure 3A). Although patients who received chemotherapy
had more advanced disease (P < 0.01, Table 2), our results
imply the efficacy of chemotherapy is still not sufficient to
overcome this disease entity. Considering inferior efficacy
of CHOP regimen for ENKTL due to frequent occurrence
of resistance to doxorubicin, we compared the cause of
death according to the type of chemotherapy regimen.
Although there was no significant difference in the
cause of deaths among patients who received CHOP or
SMILE regardless of surgery, it seemed to be that the
proportion of disease-related death was lower in patients
who received SMILE (35%, 6/17) than CHOP (57%, 21/37,
Figure 3B). However, the outcome of non-anthracycline-
based chemotherapy such as SMILE failed to show a
survival benefit compared with the CHOP regimen
(Figure 4B, C), because of high proportion of treatment
related mortality [11,12]. These results imply that in-
tensified regimens still might be insufficient to control this
disease entity and produce unacceptable toxicity lead-
ing to treatment-related morbidity and mortality. The
inferior outcome of our patients might also be related
to the fact that a substantial number of patients died
due to treatment-related complications, especially sepsis
(Figure 3A). Furthermore, nine patients had to undergo
surgery during chemotherapy due to perforation or bleed-
ing. This frequent occurrence of treatment-related
complications might be associated with the predominant
intestinal involvement by ENKTL and the aggressive nature
of this disease. Thus, much more attention is required
in monitoring of the occurrence of complications during
treatment, and active preventive approaches including
antibacterial prophylaxis might be helpful for improv-
ing treatment outcomes in these patients. There was no
unfavorable prognostic factor specific to patients with
ENKTL involving the GI tract. Univariate analysis showed
that there was an association between tumor burden
and performance status and poor OS as is seen with
other NHL.
In conclusion, ENKTL with GI tract involvement showed
predominant involvement of the small intestine. The
prognosis was extremely poor despite active treatment
including chemotherapy and surgery. In addition, treat-
ment-related mortality was also relatively high and in-
cluded cases of sepsis. Thus, a more effective treatment
strategy should be developed for this rare but fatal
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